John McEleney
Corporate Vice President of Strategy, PTC

Entrepreneur and industry luminary, John McEleney has spent his career transforming businesses, driving corporate strategy and forecasting what’s next in product development and manufacturing. With more than 30 years of experience in mechanical design and software, McEleney understands the innovation challenges customers face in today’s hyper-connected world, and helps them navigate the digital era. He is now the corporate vice president of strategy at PTC. 

In 2012, McEleney launched Onshape -- the Software-as-a-Service (SaaS) product development platform. It is the only product development platform that’s architected for the cloud, enables engineers to design products on-demand, and collaborate in real time -- without being tethered to a machine or device. Onshape was acquired in 2019 by PTC for $470 million. Previously, McEleney was the CEO of CloudSwitch, a cloud enterprise software company acquired by Verizon, and the CEO of SolidWorks, acquired by Dassault Systèmes for $310 million.

McEleney serves as a director of Stratasys Inc., a publicly held 3D printing company. He holds a Bachelor of Science in mechanical engineering from the University of Rochester, a Master of Science in manufacturing systems engineering from Boston University, and an MBA from Northeastern University.

When he is not planning global strategy or interacting with customers, McEleney enjoys skiing, golf, and adventure travel. He lives in Massachusetts with his wife, son and daughter.

Martine Rothblatt
Chairperson, CEO & Founder, United Therapeutics

Martine Rothblatt is the Chairperson & CEO of United Therapeutics Corporation (UT). She started UT to save her youngest child's life from a rare illness after having previously created SiriusXM satellite radio and other satellite communications systems. She is also responsible for several innovations in aviation and architecture, including the design and piloting of an electric helicopter to Guinness world records and creating the world's largest zero carbon footprint building. Her company is now saving hundreds of lives a year with medicines for pulmonary hypertension and neuroblastoma, and by restoring otherwise discarded donor lungs to transplantability. UT is also in pre-clinical development of manufactured kidneys, hearts and lungs to be delivered via autonomously flown electric vertical takeoff and landing (eVTOL) systems. Dr. Rothblatt led the efforts to create the first genetically-modified porcine hearts and kidneys transplanted into humans (xenotransplantation), resulting in a life-saving xeno-heart transplant in January 2022.

Dr. Rothblatt earned her Ph.D. in Medical Ethics from the Royal London College of Medicine and Dentistry after earning JD and MBA degrees from UCLA, which also recently awarded her the UCLA Medal, its highest honor. She is an inventor on several patents and the author of several books, the most recent of which pertain to artificial cognition and cyber-consciousness.